Article By:
ChinaBio® Today
Saturday, February 6, 2021 12:55 PM EDT
Shanghai Junshi Bio out-licensed US-Canada rights for its anti-PD-1 antibody to Coherus Bio in an agreement worth up to $1.1 billion. Syapse closed a $68 million growth equity investment led by China's Ally Bridge Group